Clinical trials: Sclerosis, Systemic
Morphea
Genetic Variants in Linear Localized Scleroderma
The purpose of this study is to investigate the genetic architecture of Linear Localized Scleroderma (LLS) (linear morphea) by whole exome sequencing.
- Trial name
- NCT02222038
- Testing
- skin biopsy
- Where
- 2 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- University Children's Hospital, Zurich
Scleroderma
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease.
- Trial name
- NCT02887495
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- George Washington University
Early and Severe Systemic Sclerosis
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both infusions.
- Trial name
- NCT00379431
- Testing
- Administration of rituximab and methylprednisolone
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- University Hospital, Ghent
Microstomia, Systemic Sclerosis
The Effect of a Home-based Orofacial Exercise Program on Oral Aperture of Systemic Sclerosis Patients
Systemic sclerosis is a systemic disease which may involve multiple organ systems and cause functional disabilities. Microstomia is one of the most common complications of the disease which may result in difficulties performing…
- Trial name
- NCT04336475
- Testing
- orofacial exercise program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Cukurova University
Systemic Scleroderma
BIOLOGICAL EXPLORATION OF THE VASCULAR FRACTION FROM THE ADIPOSE TISSUE OF PATIENTS WITH SCLERODERMIA
The overall objective is to propose a comprehensive analysis of the biological properties of the stromal vascular fraction evaluated in the SCLERADEC 2 clinical trial (n = 15 available) and preserved in the biological collection…
- Trial name
- sclerabio (NCT03629002)
- Testing
- Study of the gene expression profile
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Sclerosis, Scleroderma
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
- Trial name
- DAISY (NCT05925803)
- Testing
- Anifrolumab (blinded), Anifrolumab (unblinded, open label)
- Where
- 150 sites in United States, Austria and 21 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Morphea
Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study
Localized scleroderma or morphea is a fibrotic disease, imiquimod induces cytokines which inhibit fibrotic activity . We propose that topical imiquimod 5% cream is efficacious and safe in treating plaque-type morphea.
- Trial name
- NCT00230373
- Testing
- imiquimod 5% cream (Aldara)
- Where
- 3 sites in Canada
- Sponsor
- University of Alberta
Diffuse Cutaneous Systemic Sclerosis
Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
This is a prospective, multicenter, randomized, open-label, crossover study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in participants with diffuse cutaneous systemic sclerosis (dcSSc).
- Trial name
- NCT04137224
- Testing
- IgPro20, IgPro10
- Where
- 9 sites in Australia, Germany and 3 more
- Volunteers
- 27 people
- Sponsor
- CSL Behring
Systemic Sclerosis, Scleroderma
Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease
Systemic sclerosis (SSc) is characterized by autoimmunity and vasculopathy resulting in fibrosis of the skin and internal organs including the Gastrointestinal (GI) tract.
- Trial name
- Pre Med SSc GI (NCT04630782)
- Testing
- PET-MRI scan
- Where
- 5 sites in Singapore
- Volunteers
- 70 people
- Sponsor
- Singapore General Hospital
Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis
Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
Systemic sclerosis or scleroderma is an autoimmune condition that cause thickening and hardening of the skin, but can also affect internal organs.
- Trial name
- MINIMISE (NCT04927390)
- Testing
- Mycophenolate Mofetil 500mg
- Where
- 12 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University College, London
Systemic Scleroderma, Pulmonary Hypertension
Placebo Controlled Trial of Bosentan in Scleroderma Patients
The purpose of this study is to determine whether the drug Bosentan improves exercise tolerance in scleroderma patients.
- Trial name
- NCT00377455
- Testing
- Bosentan
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Georgetown University
Systemic Sclerosis
Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients
Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could…
- Trial name
- ScleroBiotique (NCT04132206)
- Testing
- stool sampling
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hôpital Européen Marseille
According to the IRB Approval
NVC Test in Order to Assess Pathological Changes in Family Members of Patient Diagnosed With SSc
Systemic sclerosis (SSc) is multisystem autoimmune disease of unknown etiology. It's characterized by activation of immune system, microvascular changes and intimal proliferation.
- Trial name
- SSc NVC (NCT02795221)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Systemic Sclerosis
Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis
This study is to evaluate the efficacy and safety of an antifibrotic agent, pirfenidone as treatment of systemic sclerosis. The primary outcome of this study is improvement of skin fibrosis.
- Trial name
- NCT03068234
- Testing
- Pirfenidone, Steroids
- Where
- China
- Volunteers
- 72 people
- Sponsor
- RenJi Hospital
Rheumatoid Arthritis, Spondyloarthritis
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
The prognosis of rheumatic diseases has improved considerably with development of therapy. However, infections are considered the most important cause of morbidity and mortality in this group of patients.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM)
- Trial name
- NCT01151644
- Testing
- Anti-pandemic H1N1 influenza vaccine
- Where
- Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Scleroderma
The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma
This study will evaluate the use of botulinum toxin for microstomia (also known as reduced oral aperture) in scleroderma patients.
- Trial name
- NCT04523506
- Testing
- Botulinum toxin(Botox)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Systemic Sclerosis, Digital Ulcers
Bosentan in Systemic Sclerosis
The effect of bosentan on digital ulcers (DU) was studied in two randomized placebo-controlled trials (RAPIDS-1 and RAPIDS-2). A limitation of these studies was the heterogeneous study population.
- Trial name
- HOME (NCT01395732)
- Testing
- Bosentan
- Where
- 10 sites in Netherlands
- Volunteers
- 18 people
- Sponsor
- Actelion
Healthy, Systemic Sclerosis
Systemic Sclerosis Clinical and Biomarker Study
The primary objective of the study is to assess the change in systemic sclerosis (SSc)-associated gastrointestinal (GI) tract symptoms over a 1-year period in participants with SSc.
- Trial name
- NCT02531009
- Volunteers
- healthy volunteers welcome
- Sponsor
- Biogen
Autoimmune Disease
Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study
Autoimmune diseases may involve nearly any organ and are characterized by abnormal activation or response of certain cells. Evidence suggests that farm work, exposure to silica from farming activities and exposure to pesticides…
- Trial name
- NCT00341198
- Where
- 3 sites in United States
- Volunteers
- 700 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)